Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT00270049 Completed - Cancer Clinical Trials

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Start date: November 1990
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of treatment with epoetin alfa versus placebo on the percentage of red blood cells in anemic patients with chronic lymphocytic (white blood cell) leukemia and its effect on the patients' quality-of-life. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

NCT ID: NCT00269763 Completed - Pain Clinical Trials

Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer

Start date: October 1987
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the clinical utility and safety of fentanyl TTS (a transdermal patch delivering the narcotic pain reliever fentanyl) in the treatment of pain in patients with cancer.

NCT ID: NCT00269737 Completed - Pain Clinical Trials

Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer

Start date: May 1986
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of continuous use of TTS fentanyl (a transdermal patch delivering the narcotic pain reliever fentanyl) for the treatment of chronic cancer pain.

NCT ID: NCT00268905 Completed - Cancer Clinical Trials

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

Start date: October 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.

NCT ID: NCT00267332 Terminated - Pain Clinical Trials

Modafinil in Opioid Induced Sedation

Start date: January 2006
Phase: Phase 3
Study type: Interventional

- The primary objective of this study is to evaluate the efficacy of modafinil in the treatment of opioid induced sedation as measured by the Epworth Sleepiness Scale (ESS). - The secondary objective is to estimate the frequency and severity of toxicity associated with Modafinil (400mg) in patients with opioid induced sedation.

NCT ID: NCT00263783 Completed - Cancer Clinical Trials

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

Start date: March 2001
Phase: Phase 1
Study type: Interventional

To determine the safety profile of single and multiple doses of MEDI522 in patients with refractory solid tumors.

NCT ID: NCT00263575 Completed - Pain Clinical Trials

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.

NCT ID: NCT00262678 Completed - Pain Clinical Trials

Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.

NCT ID: NCT00261534 Active, not recruiting - Cancer Clinical Trials

Cancer Related Fatigue in Patients Receiving Chemotherapy

Start date: January 2006
Phase: N/A
Study type: Observational

The purpose of this study is to examine the degree of fatigue in patients receiving chemotherapy. Special interest goes out to the course of fatigue throughout five treatments and the actions taken by patients to reduce this fatigue.The correlation between fatigue and haemoglobin will also be subject of study.

NCT ID: NCT00259818 Completed - Cancer Clinical Trials

Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors

Start date: December 2005
Phase: Phase 1
Study type: Interventional

This is a Phase I, dose escalation study of EM-1421 administered by intravenous infusion (IV) for five consecutive days every 28 days to patients with solid tumors refractory to current therapies. There have been no previous human studies of intravenous (into one's vein) EM-1421 treatment; however, lab research (research in test tubes and/or animals) suggests that EM-1421 has shown some activity against tumors in animals. This activity in animal models suggests that EM-1421 may be a useful chemotherapy for human cancer. The primary objective of this study is to determine the safety and maximum tolerated dose of EM-1421 given by intravenous infusion. The efficacy of the treatment will also be measured.